Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA in children and adolescents with brain tumors
2024-517575-20-00Phase 2Completed
- Sponsor
- Universität Münster
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in brain neoplasm, glioma, astrocytoma and 3 more, sponsored by Universität Münster. Primary endpoint: Incidence of grade III–V adverse events (CTCAE v4.0) related to 5-ALA fluorescence-guided resections. Started Nov 2024; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
brain neoplasmgliomaastrocytomaependymomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on 2024-517575-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517575-20-00.